Jonathan and Nir Zontag compared 438,474 diabetes patients on GLP-1 drugs with a matched group. New smell and taste problems were more common but still rare, they report in JAMA.
Recap by typeshit. Full story at Hadassah | The Women's Zionist Organization of America.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
GoodRx explains how Wegovy fits into menopause weight management and what to ask a doctor about before considering it.
Doctor Devine says more patients on GLP-1 weight loss drugs are coming in with concerns, though the specific issue is cut off.
Loading…